CYBN - Wall Street Lunch: Not An Ecstatic Day

2024-06-05 14:37:06 ET

Summary

• Shares of psychedelic medicine developers fall after the FDA panel votes against approving MDMA for PTSD treatment.
• U.S. private sector job growth falls short of expectations, raising concerns about the labor market.
• Wells Fargo's Chris Harvey comes out with a new midcap portfolio of overweight-rated stocks.

Listen below or on the go on Apple Podcasts and Spotify

An advisory panel votes against ecstasy treatment for PTSD. (0:16) Services activity picks up. (1:34) You know what they call a Chicken Big Mac in Europe? (4:14)...

For further details see: